Welcome to Blood London, where you can access a wide range of accurate and detailed blood tests related to assessing and improving fertility. We understand that navigating the complexities of fertility and reproductive health can be challenging, which is why we offer a comprehensive range of blood testing services designed to support you at every stage of your reproductive journey.
Our Fertility Test services cover a broad spectrum of reproductive health concerns, from puberty and menstrual cycle assessments to infertility diagnosis and management, as well as age-related changes in hormonal balance. At Blood London, we use cutting-edge diagnostic pathology to provide you with accurate and timely results, empowering you with the details required to make informed decisions about your reproductive health.
Explore our fertility testing options, which include:
Monitoring fertility and pregnancy health across all trimesters.
AMH and FSH Blood Testing indicating the size of the ovarian reserve and Ultrasound screening also available
Identifying potential causes of infertility in both men and women to aid in effective treatment.
Evaluating hormonal changes during menopause and andropause for comprehensive reproductive care.
Whether you are just starting to investigate your reproductive health or have been facing challenges along the way, Blood London is here to support you with expert care and personalized testing solutions.
The tests in this section cover menstrual cycle/pregnancy, infertility and ageing, and are drawn from all disciplines of diagnostic pathology.
This cycle controls female fertility and is influenced by hormone levels which impact bone health and many other aspects of female physiology. Pregnancy lasts 40 weeks and is divided into trimesters.
confirmation of pregnancy and associated tests may include:
testing is primarily directed at evaluating the actual and potential development of the baby and may include:
testing for foetal wellbeing and the health of the mother may include:
Infertility and its management is increasingly implicated in growing numbers of clinical disciplines. More recently, greater emphasis is being given to male infertility. Recent data suggests that approximately 40% of all infertility is ascribed entirely, or in part, to male factors, 40% to female factors with an additional 20% unexplained. Testing at the outset of infertility treatment can reduce some of the emotional and financial costs, as well as allowing couples to pursue other possible options.
Reaching menopause and andropause is a gradual process with modulating hormones as ovarian function declines in women, and the more gradual, less defined and highly variable effect in men. Testing may include:
| Female | Male |
|---|---|
| FSH – day 2/3 | Testosterone/Prolactin/FSH/LH |
| LH | Sex Hormone Binding Globulin |
| Oestradiol | Inhibin B (male) |
| Antimullerian Hormone (AMH) | Male Hormone Profile |
| Progesterone – day 21 | Andropause Profile |
| Female Hormone Profile | Insulin Resistance |
| Prolactin | Erectile Dysfunction |
| Impotence Profile |
| Female | Male |
|---|---|
| High Vaginal swab | Investigations for prostatitis/urethritis |
| Cervical swab | Mycoplasma Genitalium |
| Bacterial Vaginosis screen | Ureaplasma |
| Toxoplasma | Chlamydia/Gonorrhoea |
| Chlamydia/Gonorrhoea | Chlamydia in Semen |
| CMV | Hep B sAg/Hep B Core Abs/Hep C/HIV 1&2 |
| Hep B sAg/Hep B Core Abs/Hep C/HIV 1&2 | Herpes Simplex I/II by PCR |
| Herpes Simplex I/II by PCR | Semen culture |
| STI Profiles | Syphilis |
| Infection screening by PCR | STI Profiles |
| Infection screening by PCR |
| Female | Male |
|---|---|
| Well Person Profile DL6 | Fit for Fertility Male Profile |
| Zinc, Lead | Well Person Profile DL6 |
| Trace Metal Profile (blood) | Trace Metal Profile (blood) |
| Antioxidant Activity | Antioxidant Activity |
| Thyroid Profiles | Thyroid Profiles |
| Vitamin Profiles | Vitamin Profiles |
| Vitamin D (25 OH) | Vitamin D (25 OH) |
| Folate | Folate |
| Selenium | Selenium |
| Omega 3/Omega 6 | Zinc |
| Omega 3/Omega 6 | |
| Oxidative Stress (ROS) in Semen |
| Female | Male |
|---|---|
| Chromosome/Karyotype (parental) | Chromosome/Karyotype (parental) |
| Fragile X (female) | Male Hormone Profile |
| Cystic Fibrosis Screen | Y-Chromosome microdeletion |
| Tay Sachs | Fragile X Male |
| Jewish Carrier Profile | Cystic Fibrosis Screen |
| Inherited disorders (specific) | Tay Sachs |
| Jewish Carrier Profile | |
| Inherited disorders (specific) |
| Female | Male |
|---|---|
| Recurrent Miscarriage Profile | Chromosome/Karyotype (parental) |
| Reproductive Immunophenotyping (CD 3/4/8, CD 5/19, CD 16/56/69) | Y-Chromosome microdeletion |
| NK Cell Profile | Sperm DNA Fragmentation |
| Antiphosholipid Antibodies | Sperm aneuploidy |
| Lupus anticoagulant and Anticardiolipin antibodies | Infection screening |
| Thrombotic Profile | Heavy Metals (Blood) |
| Antinuclear antibodies | Male Recurrent Miscarriage Profile |
| Anti-Thyroglobulin antibodies | Oxidative Stress in Semen (Reactive Oxygen Species) |
| Chromosome/Karyotype (parental) | |
| Infection screening |
| Female |
|---|
| Antimullerian Hormone (AMH) |
| CA 125 / HE4 |
| Female |
|---|
| Polycystic Ovary Profile |
| Male |
|---|
| See Andrology |
Andrology division focuses on the single most important factor determining a man’s fertility potential – the production of healthy sperm.
A semen analysis, which provides information about sperm count, motility and morphology, has classically been used as the marker of male fertility potential. However, there are other parameters given in a semen analysis that are often neglected or overlooked; these may indicate important pathologies, such as infection, prostatic disease, immunological infertility, retrograde ejaculation, malformation or obstruction of the genital tract, tumour, and congenital or endocrine disorders.
Early diagnosis of the male factor is important in order to detect any underlying pathology, to determine the extent of infertility, and to ensure appropriate treatment. It may also avoid unnecessary investigations for the female partner, particularly if her age is a limiting factor.
For men who have had a vasectomy, clearance should only be given when there is no evidence of presence of sperm in two consecutive semen samples. It is therefore vital to ensure that results are reported according to best practice guidelines. Special clearance may be given at the doctor’s discretion when there are persistent non-motile sperm present.
